Vertex Pharmaceuticals reported a 12% increase in third-quarter revenue, reaching $3.44 billion, as patients continued migrating toward its newer cystic fibrosis therapies. Following the report, company shares rose about 1.5% in early after-hours trading.
The revenue expansion was anchored by Alyftrek, which generated $706 million during the quarter, marking a significant rise from $247 million previously. Non-cystic fibrosis revenue, spanning treatments such as Casgevy, Journavx, and Palsonify, climbed to $168 million compared to $37 million in the prior period.
Beneath the top-line growth, however, adjusted profit remained effectively flat. Vertex is currently channeling its cystic fibrosis cash flow directly into funding new product launches and absorbing corporate acquisitions, resulting in profit growth trailing behind sales momentum while these strategic investments ramp up.
Operational figures highlighted the transition within the company’s core portfolio. Alyftrek is increasingly replacing Trikafta rather than merely supplementing it, as patients shift from a twice-daily regimen to a once-a-day alternative. Although sales for Trikafta declined 8% due to the patient migration, higher net prices allowed the broader cystic fibrosis segment to maintain upward momentum.
At the same time, heavy corporate spending absorbed the financial gains. Adjusted operating income edged up by just 2%, reflecting proactive investments such as building a dedicated kidney-drug sales team before securing a commercial product, absorbing the Crinetics acquisition, and advancing Journavx. Because launch expenditures precede commercial revenue, earnings faced immediate pressure. A steeper drop in GAAP diluted earnings per share—falling to $2.56 from $4.20, while adjusted EPS slipped to $4.76 from $4.80—was driven primarily by one-time transaction costs associated with the Crinetics deal rather than shifts in the company’s tax rate.
Management adjusted its full-year revenue forecast upward, though analysts note the $50 million bump at the midpoint largely aligns with the expected contribution from newly acquired Palsonify. Concurrently, operating expense guidance moved higher, and Vertex carries new debt resulting from the transaction.
Looking ahead, market observers are monitoring upcoming regulatory and clinical milestones. The U.S. Food and Drug Administration faces a decision by November 30 regarding povetacicept for IgA nephropathy, a therapeutic area Vertex is already positioning sales infrastructure to support. Additionally, interim clinical data for VX-670 in myotonic dystrophy is anticipated before the conclusion of the year.
